Robert N. Steiner—Port Authority of New York and New Jersey, New York City, NY
R. Erik Stromberg—American Association of Port Authorities, Alexandria, VA

Non-Port Marine Terminal Operators:

Stephen T. Rudman—Matson Terminals, Inc., San Francisco, CA
Francis A. Scanlan—Port of Philadelphia Marine Terminal Association, Philadelphia, PA
Thomas D. Wilcox—National Association of Stevedores, Washington, DC
M.A. Woodall, Jr.—Lambert's Point Docks, Norfolk, VA

Freight Forwarders/Customs Brokers:

Frank Dausz—George S. Bush Company, Portland, OR
Arthur J. Fritz, Jr.—The Fritz Companies, Inc., San Francisco, CA
James Rendeiro—F.W. Meyers and Company, Inc., New York City, NY
William St. John, Jr.—W.R. Zanes & Co. of Louisiana, New Orleans, LA

NVOCCs:

Raymond P. deMember—International Association of NVOCCs, Fairfax, VA

Transportation Service Firms:

R.D. Vinick—Distribution Publications, Inc., Oakland, CA

Committee Activities

The members of the Advisory Committee on the Section 18 Study will meet publicly to review, comment on, and give appropriate advice concerning all aspects of the five-year study that the Commission is conducting under the mandate of section 18 of the Shipping Act of 1984. They will be asked to advise the Commission on what issues are important for the Commission to research in its study of the impact of the Shipping Act of 1984, the scope of questions that should be addressed, the adequacy of the Commission's present research approaches, and possible alternative research approaches and data sources.

The Commission believes that the Advisory Committee would serve an important public interest because it would afford all elements of the maritime shipping community and the public they serve an opportunity to advise the Commission as to the most appropriate method of conducting its study of the consequences of the Shipping Act. The Commission deems such input from the maritime shipping community to be necessary to achieve an efficient and thorough research process and product.

Committee Meetings

The first meeting of the Advisory Committee is scheduled for 10:00 a.m. on March 24, 1988 at the main hearing room of the Federal Maritime Commission, located on the 1st floor of 1100 L St., NW., Washington, DC. The agenda for the meeting is given below.

Agenda for First Section 18 Advisory Committee Meeting; March 24 and 25, 1988, FMC Headquarters, Washington, DC

1. Welcome Address by FMC Acting Chairman Edward J. Philbin.
2. Administrative Matters.
3. Advisory Committee Act.
4. Role of the Advisory Committee.
5. Briefing on the Purpose of Section 18 and the Study Process.
6. Study Methods Briefing.
7. Discussion of FMC/USC Symposium.
8. Discussion on Additional Research Areas.
9. Suggested Topics for Discussion at, and Date for, Next Committee Meeting.
10. Any Other Business.

The meeting will be open to the public, and a reasonable but limited amount of public seating will be provided. Members of the public may file a written statement with the Advisory Committee at that time. Any member of the public who wishes to speak at the meeting must notify the Advisory Committee's Executive Secretary, John Robert Ewers, in writing no later than 5 days prior to the date of the meeting.

Joseph C. Polking,

Secretary.

[FR Doc. 88-3793 Filed 2-22-88; 8:45 am]

BILLING CODE 6730-01-M

FEDERAL RESERVE SYSTEM

Agency Forms Under Review

February 17, 1988.

Background

Notice is hereby given of final approval of proposed information collection(s) by the Board of Governors of the Federal Reserve System (Board) under OMB delegated authority, as per 5 CFR § 1320.9 (OMB Regulations on Controlling Paperwork Burdens on the Public).

For Further Information Contact:

Federal Reserve Board Clearance Officer—Nancy Steele—Division of Research and Statistics, Board of Governors of the Federal Reserve System, Washington, DC 20551, (202-452-3822)

OMB Desk Officer—Robert Fishman—Office of Information and Regulatory Affairs, Office of Management and Budget, New Executive Office Building, Room 3228, Washington, DC 20503, (202-395-7340)

Proposal to approve under OMB delegated authority the extension, with revision, of the following reports:

1. *Report title:* Report of Condition for Foreign Subsidiaries
Agency form number: FR 2314
OMB Docket number: 7100-0073
Frequency: Annual
Reporters: Foreign subsidiaries of U.S. Member Banks, Bank Holding Companies, and Edge or Agreement Corporations
Annual reporting hours: 6606.
Small businesses are not affected.
General description of the report:

This report is required by law (12 U.S.C. 324, 1844(c), 602, and 625) and is given confidential treatment (5 U.S.C. 552(b)(4) and (b)(8)).

This report provides the only source of comprehensive and systematic data on the assets and liabilities of foreign subsidiaries of U.S. banking organizations. The data are used to monitor the growth and activities of the subsidiaries and to supervise the overall operations of the parent institutions. Its extension is proposed with minor revisions to tailor the forms to each company's reporting requirements, and to request identification of subsidiaries on consolidated reports.

2. *Report title:* Annual Report of Foreign Banking Organizations; Foreign Banking Organization Confidential Report of Operations
Agency form number: FR Y-7; FR 2068
OMB Docket number: 7100-0125
Frequency: Annual
Reporters: Foreign banking organizations
Annual reporting hours: 10,858
Small businesses are not affected.
General description of report: These reports are required by law (12 U.S.C. 1844(c), 3106 and 3108(a)) and are given confidential treatment (5 U.S.C. 552(b)(8)).

These reports request financial and structural information on foreign banking organizations and their U.S. activities in order to assess their ability to serve as a source of strength to their U.S. operations and to determine compliance with the Bank Holding Company Act and International Banking Act. They are proposed to be extended with minor technical changes and instructional clarifications, including the incorporation into the forms of items

approved in 1986 and currently collected on supplementary sheets.

Board of Governors of the Federal Reserve System, February 17, 1988.

William W. Wiles,

Secretary of the Board.

[FR Doc. 88-3720 Filed 2-22-88; 8:45 am]

BILLING CODE 6210-01-M

First National Holding Co., Inc.; Acquisition of Company Engaged in Permissible Nonbanking Activities

The organization listed in this notice has applied under § 225.23(a)(2) or (f) of the Board's Regulation Y (12 CFR 225.23(a)(2) or (f)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to acquire or control voting securities or assets of a company engaged in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than March 14, 1988.

A. **Federal Reserve Bank of Kansas City** (Thomas M. Hoenig, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. *First National Holding Company, Inc.*, Fullerton, Nebraska; to acquire Black Insurance Agency, Fullerton, Nebraska, and thereby engage in insurance agency activities in a town with a population not exceeding 5,000 pursuant to § 225.25(b)(8)(iii) of the Board's Regulation Y. This activity will be conducted in Nance County, Nebraska.

Board of Governors of the Federal Reserve System, February 17, 1988.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 88-3721-Filed 2-22-88; 8:45 am]

BILLING CODE 6210-01-M

Key Centurion Bancshares, Inc., et al.; Formations of; Acquisitions by; and Mergers of Bank Holding Companies

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulations Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement or why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than March 14, 1988.

A. **Federal Reserve Bank of Richmond** (Lloyd W. Bostian, Jr., Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. *Key Centurion Bancshares, Inc.*, Charleston, West Virginia; to acquire 100 percent of the voting shares of The Lincoln National Bank of Hamlin, Hamlin, West Virginia.

B. **Federal Reserve Bank of Kansas City** (Thomas M. Hoenig, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. *Jackson Hole Bancshares Corporation*, Jackson, Wyoming; to become a bank holding company by acquiring 83.91 percent of the voting shares of Bank of Jackson Hole, Jackson, Wyoming.

Board of Governors of the Federal Reserve System, February 17, 1988.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 88-3722 Filed 2-22-88; 8:45 am]

BILLING CODE 6210-01-M

Change in Bank Control; Acquisition of Shares of Banks or Bank Holding Companies; M.F. Jarvis Trust et al.

The notificant listed below has applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. Once the notices have been accepted for processing, they will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than March 10, 1988.

A. **Federal Reserve Bank of Kansas City** (Thomas M. Hoenig, Senior Vice President), 925 Grand Avenue, Kansas City, Missouri 64198.

1. *M.F. Jarvis Trust*, Winfield, Kansas; First National Bank of Winfield, Kansas, and Janet J. Reid, Winfield, Kansas, beneficiary of M.F. Jarvis Trust; to retain 25.32 percent of the voting shares of First National Bancshares of Winfield, Inc., Winfield, Kansas, and thereby indirectly acquire First National Bank of Winfield, Winfield, Kansas.

Board of Governors of the Federal Reserve System, February 17, 1988.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 88-3723 Filed 2-22-88; 8:45 am]

BILLING CODE 6210-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 87G-0406]

Imperial Biotechnology, Ltd.; Filing of Petition for Affirmation of GRAS Status

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a petition (GRASP 8G0335) has been filed on behalf of Imperial Biotechnology, Ltd., proposing that aminopeptidase from *Lactococcus lactis* is generally recognized as safe (GRAS) as a direct human food ingredient.

DATE: Comments by April 25, 1988.

ADDRESS: Written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 4–62, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Geraldine E. Harris, Center for Food Safety and Applied Nutrition (HFF–334), Food and Drug Administration, 200 C Street SW., Washington, DC 20204, 202–426–9463.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5)) and the regulations for affirmation of GRAS status in § 170.35 (21 CFR 170.35), notice is given that a petition (GRASP 8G0335) has been filed on behalf of Imperial Biotechnology, Ltd., Imperial College Road, South Kensington, London SW, 72BT, England, proposing that aminopeptidase from *Lactococcus lactis* is GRAS as a direct human food ingredient.

The petition has been placed on display at the Dockets Management Branch (address above).

Any petition that meets the requirements outlined in § 170.35 is filed by the agency. There is no prefiling of review of the adequacy of data to support a GRAS conclusion. Thus, the filing of a petition for GRAS affirmation should not be interpreted as a preliminary indication of suitability for GRAS affirmation.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Interested persons may, on or before April 25, 1988, review the petition and/or file comments (two copies, identified with the docket number found in brackets in the heading of this document) with the Dockets Management Branch (address above). Comments should include any available information that would be helpful in determining whether this substance is or is not GRAS. A copy of the petition and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: February 11, 1988.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 88–3782 Filed 2–22–88; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 88M–0019]

IMRE Corp.; Premarket Approval of the Prosorba® Column

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by IMRE Corp., Seattle, WA, for premarket approval, under the Medical Device Amendments of 1976, of the Prosorba® Column. After reviewing the recommendation of the Gastroenterology-Urology Devices Panel, FDA's Center for Devices and Radiological Health (CDRH) notified the applicant of the approval of the application.

DATE: Petitions for administrative review by March 24, 1988.

ADDRESS: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 4–62, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Frank, S. Casciani, Center for Devices and Radiological Health (HFZ–420), Food and Drug Administration, 8757 Georgia Ave., Silver Spring, MD 20910, 301–427–7750.

SUPPLEMENTARY INFORMATION: On July 1, 1985, IMRE Corp., Seattle, WA 98109, submitted to CDRH an application for premarket approval of the Prosorba® Column. The device is an immunoadsorption affinity column for removing immune complexes from pasma of patients with idiopathic thrombocytopenic purpura. Prosorba® Column is indicated for use in the therapeutic removal of immunoglobulin G (IgG) and IgG-containing circulating immune complexes from plasma in patients with idiopathic thrombocytopenic purpura having platelet numbers less than 100,000 per cubic millimeter.

On July 29, 1986, the Gastroenterology-Urology Devices Panel, and FDA advisory committee, reviewed and recommended approval of the application. On December 23, 1987, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

A copy of all approved labeling is available for public inspection at CDRH—contact Frank S. Casciani (HFZ–420), address above.

Opportunity for administrative Review

Section 515(d)(3) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act (21 U.S.C. 360e(g)), for administrative review of CDRH's decision to approve this application. A petitoner may request either a formal hearing under Part 12 (21 CFR Part 12) of FDA's administrative practices and procedures regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish notice of its decision in the **Federal Register.** If FDA grants the petition, the notice will state the issue to be reviewed, the form of review to be used, the persons who may participate in the review, the time and place where the review will occur, and details.

Petitioners may, at any time on or before March 24, 1988 file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information identified with the name of the device and the docket number found in brackets in the heading of this documents. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs.